Ramon Colomer

Summary

Country: Spain

Publications

  1. pmc Cancer care in rural areas
    R Colomer
    Br J Cancer 90:1688; author reply 1689. 2004
  2. ncbi Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domain
    R Colomer
    Institut Catala d Oncologia, Hospital Dr Josep Trueta, Girona, Spain
    Ann Oncol 15:201-6. 2004
  3. ncbi N-3 fatty acids, cancer and cachexia: a systematic review of the literature
    Ramon Colomer
    Medical Oncology Service, Catalan Institute of Oncology, Girona, Spain
    Br J Nutr 97:823-31. 2007
  4. ncbi Gemcitabine and paclitaxel in metastatic breast cancer: a review
    Ramon Colomer
    Medical Oncology Division, Institut Catala d Oncologia, Girona, Spain
    Oncology (Williston Park) 18:8-12. 2004
  5. ncbi Green tea catechin inhibits fatty acid synthase without stimulating carnitine palmitoyltransferase-1 or inducing weight loss in experimental animals
    Teresa Puig
    Girona Biomedical Research Institute IdIBGi and Catalan Institute of Oncology, Dr Josep Trueta University Hospital, Girona, Spain
    Anticancer Res 28:3671-6. 2008
  6. ncbi An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review)
    Laura Ferrer-Soler
    Girona Biomedical Research Institute IdIBGi, Dr Josep Trueta University Hospital of Girona, Girona, Catalonia, Spain
    Int J Mol Med 20:3-10. 2007
  7. ncbi Mediterranean diet, olive oil and cancer
    Ramon Colomer
    Medical Oncology, Institut Catala d Oncologia, Hospital de Girona Dr Josep Trueta, Girona, Spain
    Clin Transl Oncol 8:15-21. 2006
  8. ncbi Fatty acid metabolism in breast cancer cells: differential inhibitory effects of epigallocatechin gallate (EGCG) and C75
    Teresa Puig
    Fundació d Investigació Biomèdica de Girona Dr Josep Trueta IdIBGi, Hospital Universitari de Girona Dr Josep Trueta, Girona, Spain
    Breast Cancer Res Treat 109:471-9. 2008
  9. doi A cytotoxic ribonuclease reduces the expression level of P-glycoprotein in multidrug-resistant cell lines
    Jessica Castro
    Laboratori d Enginyeria de Proteïnes, Departament de Biologia, Facultat de Ciencies, Universitat de Girona, Campus de Montilivi, Maria Aurèlia Campmany, 69, 17071, Girona, Spain
    Invest New Drugs 30:880-8. 2012
  10. ncbi Interstitial pneumonitis after oxaliplatin treatment in colorectal cancer
    Xavier Hernández Yagüe
    Oncologia Medica, Institut Catala d Oncologia, Girona, Spain
    Clin Transl Oncol 7:515-7. 2005

Collaborators

Detail Information

Publications10

  1. pmc Cancer care in rural areas
    R Colomer
    Br J Cancer 90:1688; author reply 1689. 2004
  2. ncbi Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domain
    R Colomer
    Institut Catala d Oncologia, Hospital Dr Josep Trueta, Girona, Spain
    Ann Oncol 15:201-6. 2004
    ..We wanted to assess the toxicity and efficacy of paclitaxel plus gemcitabine in advanced breast cancer and to confirm whether circulating HER2 extracellular domain (ECD) correlates with treatment response...
  3. ncbi N-3 fatty acids, cancer and cachexia: a systematic review of the literature
    Ramon Colomer
    Medical Oncology Service, Catalan Institute of Oncology, Girona, Spain
    Br J Nutr 97:823-31. 2007
    ..Our findings suggest that administration of n-3 FA (EPA and DHA) in doses of at least 1.5 g/day for a prolonged period of time to patients with advanced cancer is associated with an improvement in clinical, biological and QoL parameters...
  4. ncbi Gemcitabine and paclitaxel in metastatic breast cancer: a review
    Ramon Colomer
    Medical Oncology Division, Institut Catala d Oncologia, Girona, Spain
    Oncology (Williston Park) 18:8-12. 2004
    ..Triplet combinations, in which an anthracycline is added to gemcitabine/paclitaxel, are being explored in the metastatic and neoadjuvant settings...
  5. ncbi Green tea catechin inhibits fatty acid synthase without stimulating carnitine palmitoyltransferase-1 or inducing weight loss in experimental animals
    Teresa Puig
    Girona Biomedical Research Institute IdIBGi and Catalan Institute of Oncology, Dr Josep Trueta University Hospital, Girona, Spain
    Anticancer Res 28:3671-6. 2008
    ..The use of FASN inhibitors has been limited until now by anorexia and weight loss, which is associated with the stimulation of fatty acid oxidation...
  6. ncbi An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review)
    Laura Ferrer-Soler
    Girona Biomedical Research Institute IdIBGi, Dr Josep Trueta University Hospital of Girona, Girona, Catalonia, Spain
    Int J Mol Med 20:3-10. 2007
    ....
  7. ncbi Mediterranean diet, olive oil and cancer
    Ramon Colomer
    Medical Oncology, Institut Catala d Oncologia, Hospital de Girona Dr Josep Trueta, Girona, Spain
    Clin Transl Oncol 8:15-21. 2006
    ..Indeed, OA-induced transcriptional repression of HER2 oncogene may represent a novel genomic explanation linking "Mediterranean diet", olive oil and cancer as it seems to equally operate in various types of Her-2/neu-related carcinomas...
  8. ncbi Fatty acid metabolism in breast cancer cells: differential inhibitory effects of epigallocatechin gallate (EGCG) and C75
    Teresa Puig
    Fundació d Investigació Biomèdica de Girona Dr Josep Trueta IdIBGi, Hospital Universitari de Girona Dr Josep Trueta, Girona, Spain
    Breast Cancer Res Treat 109:471-9. 2008
    ..Our results establish EGCG as a potent and specific inhibitor of fatty acid synthesis (FASN), which may hold promise as a target-directed anti-cancer drug...
  9. doi A cytotoxic ribonuclease reduces the expression level of P-glycoprotein in multidrug-resistant cell lines
    Jessica Castro
    Laboratori d Enginyeria de Proteïnes, Departament de Biologia, Facultat de Ciencies, Universitat de Girona, Campus de Montilivi, Maria Aurèlia Campmany, 69, 17071, Girona, Spain
    Invest New Drugs 30:880-8. 2012
    ..In conclusion, PE5 is a cytotoxic ribonuclease that cleaves nuclear RNA and decreases the expression of P-glycoprotein, showing anticancer activity in multidrug-resistant cell lines...
  10. ncbi Interstitial pneumonitis after oxaliplatin treatment in colorectal cancer
    Xavier Hernández Yagüe
    Oncologia Medica, Institut Catala d Oncologia, Girona, Spain
    Clin Transl Oncol 7:515-7. 2005
    ..The patient died 20 days after admission due to irreversible respiratory failure. This is the first case reported in the literature of interstitial pneumonitis related to single-agent oxaliplatin administration...